Optimal dose of intravenous tenecteplase for acute ischemic stroke in China: A prospective, multicenter, registry study
Brain Circulation · 15.07.2026
DOI: 10.4103/bc.bc_1_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Circulation, online erschienen am 15.07.2026. Verfasst von Yu Cui und 19 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Although intravenous tenecteplase (TNK) at 0.25 mg/kg is guideline-endorsed for stroke, the ideal dosage for maximizing efficacy while minimizing risk has not been definitively established. This investigation aimed to identify the optimal TNK dose through a prospective, multicenter registry in a Chinese cohort. METHODS: Consecutive stroke patients receiving intravenous TNK, with or without endovascular therapy, were enrolled. TNK was administered as either a fixed 16 mg bolus or a weight-adjusted dose of 0.25 mg/kg (maximum 16 mg), per physician judgment. Utilizing restricted cubic spline analysis of the mg/kg dose, participants were stratified into six dose categories. Efficacy endpoint was an excellent functional outcome (90-day modified Rankin Scale scoring 0–1), and safety endpoint was symptomatic intracranial hemorrhage (sICH). RESULTS: The final analysis comprised 993 of 1,000 initially enrolled patients. Rates of excellent functional outcome were: 59.9% (≤ 0.20 mg/kg), 65.7% (0.21–0.22 mg/kg), 63.9% (0.23–0.24 mg/kg), 60.0% (0.26–0.27 mg/kg), and 53.5% (≥ 0.28 mg/kg). No statistically significant differences were observed relative to the 0.25 mg/kg reference group (61.0%). The incidence of sICH was 1.4% in the reference group, with other groups ranging from 1.0% to 2.9%. CONCLUSIONS: This real-world analysis suggests that a TNK dose range of 0.21–0.24 mg/kg may be associated with a nonsignificant trend toward better 90-day outcomes and a favorable safety profile compared to the standard 0.25 mg/kg dose in Chinese stroke patients, warranting further validation. TRIAL REGISTRATION: http://www.clinicaltrials.gov (identifier: NCT04588337).
Zitieren
APA
Cui, Y., Wang, X., Bao, X., Shen, L., Zhao, L., Zhang, Y., Geng, S., Wang, S., Liang, Y., Li, J., Duan, Y., Kong, N., Ma, Y., Wan, L., Sun, H., Wang, W., Cao, Q., Bao, Y., Nguyen, T. N., & Chen, H. (2026). Optimal dose of intravenous tenecteplase for acute ischemic stroke in China: A prospective, multicenter, registry study. Brain Circulation. https://doi.org/10.4103/bc.bc_1_26
Vancouver
Cui Y, Wang X, Bao X, Shen L, Zhao L, Zhang Y, et al. Optimal dose of intravenous tenecteplase for acute ischemic stroke in China: A prospective, multicenter, registry study. Brain Circulation. 2026. doi:10.4103/bc.bc_1_26
BibTeX
@article{Cui2026,
author = {Cui, Yu and Wang, Xin-Hong and Bao, Xu and Shen, Li-Ying and Zhao, Li-Wei and Zhang, Yi and Geng, Shi-Mei and Wang, Shu-Yao and Liang, Yong and Li, Jing and Duan, Ying-Jie and Kong, Nan and Ma, Yu-Tong and Wan, Li-Shu and Sun, Hong-Xia and Wang, Wei-Zhong and Cao, Qun and Bao, Ying and Nguyen, Thanh N. and Chen, Hui-Sheng},
title = {Optimal dose of intravenous tenecteplase for acute ischemic stroke in China: A prospective, multicenter, registry study},
journal = {Brain Circulation},
year = {2026},
doi = {10.4103/bc.bc_1_26}
}
EUVIMED